Loading…
Pharmacokinetics and metabolism of N-(2-hydroxyethyl)-2,5-[14C]-pyrrolidine (HEP, Epolamine) in male healthy volunteers
N-(2-hydroxyethyl)-pyrrolidine (HEP, Epolamine) is a strong base used to salify organic acids of pharmaceutical interest in order to improve their solubility in water. Diclofenac-HEP (Flector) is the first example of an epolamine salt of a drug. In this study, [14C]-HEP was administered by oral rout...
Saved in:
Published in: | European journal of drug metabolism and pharmacokinetics 1996-07, Vol.21 (3), p.261-268 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c311t-6e20eb0a7d93ff0f28b8c25881ff49785189a29687ab7873020868e407043cb03 |
---|---|
cites | cdi_FETCH-LOGICAL-c311t-6e20eb0a7d93ff0f28b8c25881ff49785189a29687ab7873020868e407043cb03 |
container_end_page | 268 |
container_issue | 3 |
container_start_page | 261 |
container_title | European journal of drug metabolism and pharmacokinetics |
container_volume | 21 |
creator | GIACHETTI, C ASSANDRI, A MAUTONE, G TAJANA, E PALUMBO, B PALUMBO, R |
description | N-(2-hydroxyethyl)-pyrrolidine (HEP, Epolamine) is a strong base used to salify organic acids of pharmaceutical interest in order to improve their solubility in water. Diclofenac-HEP (Flector) is the first example of an epolamine salt of a drug. In this study, [14C]-HEP was administered by oral route (300 mg, about 50 microCi/subject) to 3 volunteers with the aim to investigate its plasma profile and to calculate the relevant pharmacokinetic parameters. The experimental data correlated with a two-compartment pharmacokinetic model. Total radioactivity in urine and faeces was also measured. The radioactivity was excreted preferentially by the faecal route (about 65% of the dose administered in the 0-72 h collection interval). Urinary excretion accounted for about 30% of the dose and occurred very rapidly (about 22% of the dose was in the 0-8 h collection interval). Metabolic investigations were carried out on urine samples. TLC analysis with radioscan detector indicated a main radioactive zone, accounting for about 98% of the radioactivity in the plate. After scraping off and purification of the radioactive areas, the compound isolated (Met I) was analysed by gas chromatography-mass spectrometry with electron-impact ionization process. The structure of the metabolite was postulated to be pyrrolidine N-oxide. |
doi_str_mv | 10.1007/bf03189724 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78644302</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78644302</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-6e20eb0a7d93ff0f28b8c25881ff49785189a29687ab7873020868e407043cb03</originalsourceid><addsrcrecordid>eNo9kEFr3DAQhUVISJc0l94DOpSwKVE7kmxrfGyXTRMISQ7tqQQjyxLrVrY2kret_30Vss1chuF978E8Qt5x-MgB1KfWgeRYK1EckIXgoBhwhEOyAKmQqbqq3pDTlH5CHol1WVbH5BhrhFpUC_LnYaPjoE341Y926k2ieuzoYCfdBt-ngQZH79hSsM3cxfB3ttNm9hdMXJbsBy9Wj2w7x5jJLtvp8nr9cEnX2-D1kO8L2o900N7SjdU-G-nv4HfjZG1Mb8mR0z7Z0_0-Id-v1t9W1-z2_uvN6vMtM5LziVVWgG1Bq66WzoET2KIRJSJ3rqgVlvlzLeoKlW4VKgkCsEJbgIJCmhbkCTl_yd3G8LSzaWqGPhnrvR5t2KVGYVUU2ZbBDy-giSGlaF2zjf2g49xwaJ6Lbr5c_S86w2f71F072O4V3dea9fd7XSejvYt6NH16xUQpUICS_wBPnIK6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78644302</pqid></control><display><type>article</type><title>Pharmacokinetics and metabolism of N-(2-hydroxyethyl)-2,5-[14C]-pyrrolidine (HEP, Epolamine) in male healthy volunteers</title><source>Alma/SFX Local Collection</source><creator>GIACHETTI, C ; ASSANDRI, A ; MAUTONE, G ; TAJANA, E ; PALUMBO, B ; PALUMBO, R</creator><creatorcontrib>GIACHETTI, C ; ASSANDRI, A ; MAUTONE, G ; TAJANA, E ; PALUMBO, B ; PALUMBO, R</creatorcontrib><description>N-(2-hydroxyethyl)-pyrrolidine (HEP, Epolamine) is a strong base used to salify organic acids of pharmaceutical interest in order to improve their solubility in water. Diclofenac-HEP (Flector) is the first example of an epolamine salt of a drug. In this study, [14C]-HEP was administered by oral route (300 mg, about 50 microCi/subject) to 3 volunteers with the aim to investigate its plasma profile and to calculate the relevant pharmacokinetic parameters. The experimental data correlated with a two-compartment pharmacokinetic model. Total radioactivity in urine and faeces was also measured. The radioactivity was excreted preferentially by the faecal route (about 65% of the dose administered in the 0-72 h collection interval). Urinary excretion accounted for about 30% of the dose and occurred very rapidly (about 22% of the dose was in the 0-8 h collection interval). Metabolic investigations were carried out on urine samples. TLC analysis with radioscan detector indicated a main radioactive zone, accounting for about 98% of the radioactivity in the plate. After scraping off and purification of the radioactive areas, the compound isolated (Met I) was analysed by gas chromatography-mass spectrometry with electron-impact ionization process. The structure of the metabolite was postulated to be pyrrolidine N-oxide.</description><identifier>ISSN: 0378-7966</identifier><identifier>EISSN: 2107-0180</identifier><identifier>DOI: 10.1007/bf03189724</identifier><identifier>PMID: 8980926</identifier><language>eng</language><publisher>Genève: Médecine et hygiène</publisher><subject>Adult ; Biological and medical sciences ; Carbon Radioisotopes ; Feces - chemistry ; Gas Chromatography-Mass Spectrometry ; General pharmacology ; Humans ; Male ; Medical sciences ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Pyrrolidines - blood ; Pyrrolidines - metabolism ; Pyrrolidines - pharmacokinetics ; Pyrrolidines - urine</subject><ispartof>European journal of drug metabolism and pharmacokinetics, 1996-07, Vol.21 (3), p.261-268</ispartof><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-6e20eb0a7d93ff0f28b8c25881ff49785189a29687ab7873020868e407043cb03</citedby><cites>FETCH-LOGICAL-c311t-6e20eb0a7d93ff0f28b8c25881ff49785189a29687ab7873020868e407043cb03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2528207$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8980926$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GIACHETTI, C</creatorcontrib><creatorcontrib>ASSANDRI, A</creatorcontrib><creatorcontrib>MAUTONE, G</creatorcontrib><creatorcontrib>TAJANA, E</creatorcontrib><creatorcontrib>PALUMBO, B</creatorcontrib><creatorcontrib>PALUMBO, R</creatorcontrib><title>Pharmacokinetics and metabolism of N-(2-hydroxyethyl)-2,5-[14C]-pyrrolidine (HEP, Epolamine) in male healthy volunteers</title><title>European journal of drug metabolism and pharmacokinetics</title><addtitle>Eur J Drug Metab Pharmacokinet</addtitle><description>N-(2-hydroxyethyl)-pyrrolidine (HEP, Epolamine) is a strong base used to salify organic acids of pharmaceutical interest in order to improve their solubility in water. Diclofenac-HEP (Flector) is the first example of an epolamine salt of a drug. In this study, [14C]-HEP was administered by oral route (300 mg, about 50 microCi/subject) to 3 volunteers with the aim to investigate its plasma profile and to calculate the relevant pharmacokinetic parameters. The experimental data correlated with a two-compartment pharmacokinetic model. Total radioactivity in urine and faeces was also measured. The radioactivity was excreted preferentially by the faecal route (about 65% of the dose administered in the 0-72 h collection interval). Urinary excretion accounted for about 30% of the dose and occurred very rapidly (about 22% of the dose was in the 0-8 h collection interval). Metabolic investigations were carried out on urine samples. TLC analysis with radioscan detector indicated a main radioactive zone, accounting for about 98% of the radioactivity in the plate. After scraping off and purification of the radioactive areas, the compound isolated (Met I) was analysed by gas chromatography-mass spectrometry with electron-impact ionization process. The structure of the metabolite was postulated to be pyrrolidine N-oxide.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Carbon Radioisotopes</subject><subject>Feces - chemistry</subject><subject>Gas Chromatography-Mass Spectrometry</subject><subject>General pharmacology</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyrrolidines - blood</subject><subject>Pyrrolidines - metabolism</subject><subject>Pyrrolidines - pharmacokinetics</subject><subject>Pyrrolidines - urine</subject><issn>0378-7966</issn><issn>2107-0180</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><recordid>eNo9kEFr3DAQhUVISJc0l94DOpSwKVE7kmxrfGyXTRMISQ7tqQQjyxLrVrY2kret_30Vss1chuF978E8Qt5x-MgB1KfWgeRYK1EckIXgoBhwhEOyAKmQqbqq3pDTlH5CHol1WVbH5BhrhFpUC_LnYaPjoE341Y926k2ieuzoYCfdBt-ngQZH79hSsM3cxfB3ttNm9hdMXJbsBy9Wj2w7x5jJLtvp8nr9cEnX2-D1kO8L2o900N7SjdU-G-nv4HfjZG1Mb8mR0z7Z0_0-Id-v1t9W1-z2_uvN6vMtM5LziVVWgG1Bq66WzoET2KIRJSJ3rqgVlvlzLeoKlW4VKgkCsEJbgIJCmhbkCTl_yd3G8LSzaWqGPhnrvR5t2KVGYVUU2ZbBDy-giSGlaF2zjf2g49xwaJ6Lbr5c_S86w2f71F072O4V3dea9fd7XSejvYt6NH16xUQpUICS_wBPnIK6</recordid><startdate>19960701</startdate><enddate>19960701</enddate><creator>GIACHETTI, C</creator><creator>ASSANDRI, A</creator><creator>MAUTONE, G</creator><creator>TAJANA, E</creator><creator>PALUMBO, B</creator><creator>PALUMBO, R</creator><general>Médecine et hygiène</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19960701</creationdate><title>Pharmacokinetics and metabolism of N-(2-hydroxyethyl)-2,5-[14C]-pyrrolidine (HEP, Epolamine) in male healthy volunteers</title><author>GIACHETTI, C ; ASSANDRI, A ; MAUTONE, G ; TAJANA, E ; PALUMBO, B ; PALUMBO, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-6e20eb0a7d93ff0f28b8c25881ff49785189a29687ab7873020868e407043cb03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Carbon Radioisotopes</topic><topic>Feces - chemistry</topic><topic>Gas Chromatography-Mass Spectrometry</topic><topic>General pharmacology</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyrrolidines - blood</topic><topic>Pyrrolidines - metabolism</topic><topic>Pyrrolidines - pharmacokinetics</topic><topic>Pyrrolidines - urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GIACHETTI, C</creatorcontrib><creatorcontrib>ASSANDRI, A</creatorcontrib><creatorcontrib>MAUTONE, G</creatorcontrib><creatorcontrib>TAJANA, E</creatorcontrib><creatorcontrib>PALUMBO, B</creatorcontrib><creatorcontrib>PALUMBO, R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of drug metabolism and pharmacokinetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GIACHETTI, C</au><au>ASSANDRI, A</au><au>MAUTONE, G</au><au>TAJANA, E</au><au>PALUMBO, B</au><au>PALUMBO, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacokinetics and metabolism of N-(2-hydroxyethyl)-2,5-[14C]-pyrrolidine (HEP, Epolamine) in male healthy volunteers</atitle><jtitle>European journal of drug metabolism and pharmacokinetics</jtitle><addtitle>Eur J Drug Metab Pharmacokinet</addtitle><date>1996-07-01</date><risdate>1996</risdate><volume>21</volume><issue>3</issue><spage>261</spage><epage>268</epage><pages>261-268</pages><issn>0378-7966</issn><eissn>2107-0180</eissn><abstract>N-(2-hydroxyethyl)-pyrrolidine (HEP, Epolamine) is a strong base used to salify organic acids of pharmaceutical interest in order to improve their solubility in water. Diclofenac-HEP (Flector) is the first example of an epolamine salt of a drug. In this study, [14C]-HEP was administered by oral route (300 mg, about 50 microCi/subject) to 3 volunteers with the aim to investigate its plasma profile and to calculate the relevant pharmacokinetic parameters. The experimental data correlated with a two-compartment pharmacokinetic model. Total radioactivity in urine and faeces was also measured. The radioactivity was excreted preferentially by the faecal route (about 65% of the dose administered in the 0-72 h collection interval). Urinary excretion accounted for about 30% of the dose and occurred very rapidly (about 22% of the dose was in the 0-8 h collection interval). Metabolic investigations were carried out on urine samples. TLC analysis with radioscan detector indicated a main radioactive zone, accounting for about 98% of the radioactivity in the plate. After scraping off and purification of the radioactive areas, the compound isolated (Met I) was analysed by gas chromatography-mass spectrometry with electron-impact ionization process. The structure of the metabolite was postulated to be pyrrolidine N-oxide.</abstract><cop>Genève</cop><pub>Médecine et hygiène</pub><pmid>8980926</pmid><doi>10.1007/bf03189724</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0378-7966 |
ispartof | European journal of drug metabolism and pharmacokinetics, 1996-07, Vol.21 (3), p.261-268 |
issn | 0378-7966 2107-0180 |
language | eng |
recordid | cdi_proquest_miscellaneous_78644302 |
source | Alma/SFX Local Collection |
subjects | Adult Biological and medical sciences Carbon Radioisotopes Feces - chemistry Gas Chromatography-Mass Spectrometry General pharmacology Humans Male Medical sciences Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Pyrrolidines - blood Pyrrolidines - metabolism Pyrrolidines - pharmacokinetics Pyrrolidines - urine |
title | Pharmacokinetics and metabolism of N-(2-hydroxyethyl)-2,5-[14C]-pyrrolidine (HEP, Epolamine) in male healthy volunteers |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T02%3A35%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacokinetics%20and%20metabolism%20of%20N-(2-hydroxyethyl)-2,5-%5B14C%5D-pyrrolidine%20(HEP,%20Epolamine)%20in%20male%20healthy%20volunteers&rft.jtitle=European%20journal%20of%20drug%20metabolism%20and%20pharmacokinetics&rft.au=GIACHETTI,%20C&rft.date=1996-07-01&rft.volume=21&rft.issue=3&rft.spage=261&rft.epage=268&rft.pages=261-268&rft.issn=0378-7966&rft.eissn=2107-0180&rft_id=info:doi/10.1007/bf03189724&rft_dat=%3Cproquest_cross%3E78644302%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c311t-6e20eb0a7d93ff0f28b8c25881ff49785189a29687ab7873020868e407043cb03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=78644302&rft_id=info:pmid/8980926&rfr_iscdi=true |